Study aimed to develop a CSFV Erns IgG AlphaLISA® for serum and oral fluids that would complement currently available CSFV E2 DIVA vaccines.
Study aimed to develop a CSFV Erns IgG AlphaLISA® for serum and oral fluids that would complement currently available CSFV E2 DIVA vaccines.